Revolutionizing the Way We Treat Complex Disorders: An Interview With the Founder of Kurve Therapeutics and a Special Podcast Episode Invitation

In today’s fast-paced and ever-evolving world, it’s exciting to come across innovative solutions that make our lives easier and improve our health. Kurve Therapeutics is a prime example of this. Kurve was founded by a developer seeking a better solution to his chronic sinusitis. What started as a quest to improve his health has turned into a groundbreaking technology capable of treating complex disorders such as Alzheimer’s, Parkinson’s, and ALS, to name a few. In this interview, we delve deeper into the technology behind Kurve Therapeutics and how it’s turning the tide on cognitive aging.

If you’d like to hear more about how Kurve Therapeutics treats complex Central Nervous System disorders, we invite you to listen to Kurve’s “Reclaim the Brain” podcast. In episode 1, Kurve’s founder and CEO, Marc Giroux, dives into the company’s mission and approach.

Listen now on Spotify:

Spotify Icon Listen Now

While researching how to treat his chronic sinusitis better, Marc discovered that the traditional way of delivering medicine to the nasal cavity was ineffective. Most people don’t realize that there’s a lot of empty space behind their faces, and spray bottles were not effectively accessing the nasal cavity. Marc’s goal was not only to get medicine all the way through the nasal cavity but also to penetrate the paranasal sinuses — something traditional nasal sprays cannot do.

After researching the science and physics behind fluid dynamics in the nasal cavity, he came up with a solution that reached the roof of the nasal cavity and went all the way back to the ears. The technology was so effective that it opened up opportunities for topical, systemic therapies and central nervous system disorder treatments that can now be accessed through the olfactory region. Kurve Therapeutics is the only company that has proven it can penetrate the brain through the neuronal pathway inside the nasal cavity.

Clinical trials are currently underway in various areas, including PTSD, traumatic brain injury, Parkinson’s, Alzheimer’s, multiple sclerosis, and diabetes, all of which come with cognition issues. The company has a lot of data to support its success, with 18 peer-reviewed studies on nose-to-brain drug delivery. Kurve Therapeutics is outpacing its competition, which is now only focused on systemic treatments. The company’s only main competitors are the infusion companies, who insist that they can treat these disorders chemically and through the circulatory system.

However, infusions are ineffective and only deliver less than one-tenth of 1% of medication to the brain. Infusions are incredibly expensive, costing anywhere from $5,000 to $10,000 a month, and require patients to sit in a chair for up to three hours. Kurve Therapeutics, on the other hand, gets 3,000% more into the brain than infusions and can reduce the dose significantly, making treatments much more effective and cost-efficient.

Kurve’s patented technology has another key feature its competitors do not — dose flexibility. By having control over dose flexibility and delivering higher amounts of medication to the brain than infusions and oral medications, Kurve’s technology has shown the ability to reduce systemic side effects in clinical trials by operating at a lower dose more effectively. In thousands of patients tested, Kurve Therapeutics has had zero brain bleeds, while its competition faces brain bleeds in a significant percentage of its patients.

In short, Kurve Therapeutics is revolutionizing the way we treat complex disorders. The technology Kurve has developed is more effective than traditional treatments, less invasive, and more cost-efficient. By continuously meeting its clinical trial endpoints and significant peer-reviewed studies, Kurve Therapeutics is poised to become a game-changer in the medical world. Kurve’s founder, Marc Giroux, aims to help as many people as possible with his patented technology and sees a bright future for patients suffering from neurodegenerative diseases. Alzheimer’s is just the start for Kurve Therapeutics — as Marc says, “There’s a lot more that we can do in the future,” and we’re excited to see what’s next for Kurve Therapeutics.

Don’t forget to check out Episode 1 of “Reclaim the Brain,” where Marc discusses how Kurve Therapeutics is working to treat complex Central Nervous System disorders. This insightful conversation will give you a better understanding of the company’s innovative approach and how it has the potential to transform lives.

Spotify Icon Listen Now

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037
(425) 640-9249

Transfer Agent: KoreConX Inc.  |  Broker-Dealer: Rialto Markets LLC  |  Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted.  Please contact with questions regarding a cancelation or refund.

  • Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.
  • Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.
  • Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.
  • Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.
  • Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.
  • Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.